Want to see MLTX full AI Analyst Report?
MLTX Stock Chart & Stats
$19.02
$0.84(4.42%)
At close: 4:00 PM EDT
$19.02
$0.84(4.42%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume138.32K
Average Volume (3M)1.33M
Market Cap
$1.34B
Enterprise Value$1.00K
Total Cash (Recent Filing)$537.03M
Total Debt (Recent Filing)$101.53M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Nov 17, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.85
Shares Outstanding85,106,680
10 Day Avg. Volume986,967
30 Day Avg. Volume1,328,862
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-4.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$38.00Price Target Upside99.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical & Regulatory De-riskingPositive Phase 3 data and a constructive FDA pre‑BLA meeting create a clearer regulatory path for sonelokimab, enabling a planned BLA submission. This materially reduces regulatory execution risk, accelerates potential U.S. launch sequencing and strengthens long‑term commercial optionality across indications.
Near-term Liquidity RunwayA large cash balance and an available $400M debt facility support operations and late‑stage trials through key regulatory milestones and potential launch preparation. This funding flexibility reduces near‑term financing risk and allows focus on clinical execution and regulatory filings.
Secured Commercial Manufacturing CapacityA long‑term manufacturing agreement with dedicated filling capacity de‑risks scale‑up for eventual commercialization, improving supply reliability and launch readiness. Having a committed CDMO partner supports timely product availability and operational planning for multiple indications.
Bears Say
High And Growing Cash BurnOperating cash outflows have widened materially year over year, producing sustained negative free cash flow. This structural burn means the company will remain dependent on external financing to fund development and commercialization, increasing execution risk if capital markets tighten.
Pre-revenue With Widening LossesAs a pre‑commercial biotech, MoonLake currently generates no product revenue while R&D and SG&A push losses wider. Persistent negative returns on equity and growing deficits limit internal funding capacity and magnify the consequences of any clinical or regulatory setbacks on long‑term viability.
Dilution And Financing Risk From Recent OfferingRaising capital via a sizable equity offering eases near‑term liquidity needs but dilutes existing shareholders and signals continued reliance on external funding. Combined with rising debt, ongoing financings can pressure shareholder value and increase the company's sensitivity to capital markets conditions.
MoonLake Immunotherapeutics News
MLTX FAQ
What was Moonlake Immunotherapeutics’s price range in the past 12 months?
Moonlake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is Moonlake Immunotherapeutics’s market cap?
Moonlake Immunotherapeutics’s market cap is $1.34B.
When is Moonlake Immunotherapeutics’s upcoming earnings report date?
Moonlake Immunotherapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 86 days.
How were Moonlake Immunotherapeutics’s earnings last quarter?
Moonlake Immunotherapeutics released its earnings results on Aug 10, 2026. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.909 by $0.069.
Is Moonlake Immunotherapeutics overvalued?
According to Wall Street analysts Moonlake Immunotherapeutics’s price is currently Undervalued.
Does Moonlake Immunotherapeutics pay dividends?
Moonlake Immunotherapeutics does not currently pay dividends.
What is Moonlake Immunotherapeutics’s EPS estimate?
Moonlake Immunotherapeutics’s EPS estimate is -0.79.
How many shares outstanding does Moonlake Immunotherapeutics have?
Moonlake Immunotherapeutics has 85,106,680 shares outstanding.
What happened to Moonlake Immunotherapeutics’s price movement after its last earnings report?
Moonlake Immunotherapeutics reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.909. Following the earnings report the stock price went down -5.093%.
Which hedge fund is a major shareholder of Moonlake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MoonLake Immunotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (99.79% Upside)
$38.00 (99.79% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 94%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 456.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 12.8%
Last 30 Days ▲ 12.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-65.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.75%
Trailing 12-Months
Company Description
Moonlake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$38.00
▲(99.79% Upside)
Technical Analysis
Ownership Overview
28.99% Insiders
1.78% Mutual Funds
54.78% Other Institutional Investors
13.65% Public Companies and
Individual Investors